ACE and prostate carcinoma: Subgroup analysis also showed no significant relationship between the use of ACE inhibitor and the risk of prostate cancer according to the poolanalysis of cohort studies (RR0.92, 95% CI0.77–1.11) and case-control studies (RR1.11, 95% CI0.98–1.26) (Fig. 2).